{"id":"NCT04638660","sponsor":"Ocuphire Pharma, Inc.","briefTitle":"Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances","officialTitle":"Randomized, Placebo-Controlled, Double-Masked Study of the Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-12-30","primaryCompletion":"2022-05-19","completion":"2022-05-19","firstPosted":"2020-11-20","resultsPosted":"2023-08-09","lastUpdate":"2025-09-05"},"enrollment":144,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Dim Light Vision Disturbances"],"interventions":[{"type":"DRUG","name":"Phentolamine Ophthalmic Solution 0.75%","otherNames":["Nyxol","NyxolÂ®"]},{"type":"DRUG","name":"Phentolamine Ophthalmic Solution Vehicle (Placebo)","otherNames":[]}],"arms":[{"label":"Phentolamine Ophthalmic Solution 0.75%","type":"EXPERIMENTAL"},{"label":"Phentolamine Ophthalmic Solution Vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"The objectives of this study are:\n\n* To evaluate the efficacy of Nyxol to improve mesopic low contrast visual acuity (mLCVA) in subjects with Dim Light Vision Disturbances (DLD)\n* To evaluate efficacy of Nyxol to improve visual performance\n* To evaluate the safety of Nyxol","primaryOutcome":{"measure":"Percent of Subjects With 3 Lines mLCVA Improvement in Study Eye","timeFrame":"8 days","effectByArm":[{"arm":"Phentolamine Ophthalmic Solution 0.75%","deltaMin":9,"sd":null},{"arm":"Phentolamine Ophthalmic Solution Vehicle","deltaMin":2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":17,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":71},"commonTop":["Instillation site pain","Dysgeusia","Conjunctival Hyperaemia","Instillation site erythema"]}}